Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Clinical trial NCT04848064 · RECRUITING

Trial details

NCT number: NCT04848064
Sponsor: John Reneau
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Adult T-Cell Leukemia/Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Adult T-Cell Leukemia/Lymphoma Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Start date: 2022-05-06
Primary completion: 2026-10-30
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.